Business Wire

Coagulo Medical Technologies Announces $6.5 Million in Financing to Accelerate Delivery of Disruptive Coagulation Diagnostics Platform

Share

Coagulo Medical Technologies, an MIT-born startup that has developed the world’s first precision-medicine platform for comprehensive and targeted blood clotting management, today announced it has raised $6.5 million in financing from 20/20 HealthCare Partners, Sands Capital, Good Growth Capital, IAG Capital Partners and private investors. The Boston area diagnostics innovator also announced that it has been awarded a Small Business Innovation Research (SBIR) grant by the National Science Foundation to accelerate delivery of breakthrough innovations amid the global COVID–19 public health crisis, which has called attention to the limitations of conventional coagulation tests.

Coagulo’s rapid, point-of-care device is a major advancement for personalized diagnosis and management of all coagulation-related diseases. The device is ultra-portable, requires just drops of blood and will provide vital, clinically-actionable information within 10 minutes. It leverages a proprietary and entirely novel approach to coagulation testing, which is capable of parsing through the entire coagulation cascade to pinpoint deficiency or inhibition of specific coagulation factors and quantifies their effect on clotting time.

Current coagulation testing methods were developed over a half-century ago, provide only general information on blood clotting function and cannot identify the specific cause of a clotting abnormality. Outdated testing technology is akin to a generic check engine light, whereas Coagulo’s test is designed to isolate the issue down to a specific diagnostic code. “The device promises better health outcomes by permitting physicians to supplement clinical intuition with targeted information that they always wanted but no other technology could deliver,” said Dr. Galit Frydman, CSO and President of the company. “To be able to seamlessly deliver those comprehensive, sample-to-insight results using merely drops of blood, and to have that information within a clinically meaningful timeframe and at the bedside, will make Coagulo’s diagnostic platform a critical tool in meeting the ever-evolving challenges of coagulation management,” added Jarrod Niebloom, Coagulo’s CEO and Chairman of the Board of Directors. “No doubt the complex clotting issues that continue to be observed in patients with COVID–19 epitomize just how antiquated existing diagnostic tools are and how pressing the clinical need is.”

“Coagulo has developed a platform that directly responds to current medical needs and, further, will support traditional tests like prothrombin time and activated partial thromboplastin time,” said Hillel Bachrach, managing partner of 20/20 HealthCare Partners. “We are excited to invest in Coagulo and to help accelerate their path to market as they up-end an industry that has seen very little innovation for decades.”

20/20 HealthCare Partners, a global investment group based in Boston that invests at the early stage of technology and life science innovation, has led the investment.

About Coagulo:

Founded in 2018 and based out of Alexandria LaunchLabs, Coagulo licensed technology out of MIT and the Massachusetts General Hospital (MGH) developed by Dr. Galit Frydman, the company’s CSO and President, who also holds appointments in the Division of Trauma, Emergency Surgery and Surgical Critical Care at MGH and in the Center for Biomedical Engineering at MIT. Coagulo has developed the next-generation of rapid, ultra-portable and comprehensive diagnostics for the personalized diagnosis and management of all coagulation-related diseases. Coagulo’s point-of-care device is not yet approved or cleared by the U.S. Food and Drug Administration for marketing in the United States.

www.coagulomed.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jarrod Niebloom
info@coagulomed.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye